AMENDMENTS TO THE CLAIMS

Please amend the Claims as follows.

Claims 1-22 (Cancelled)

23. (Twice Amended) A method of transfecting antigen presenting cells, the steps comprising

selecting a gene delivery complex comprising DNA and a compound selected from the group consisting of sugars, polyethylenimine, and polyethylenimine derivatives and mixtures thereof,

and applying the complex to the skin or mucosa surfaces of an animal, wherein said DNA comprises a nucleic acid sequence encoding at least one immunogenic protein operatively linked to a promoter, wherein the immunogenic protein is from a lentivirus.

- 24. The method of Claim 23, wherein the compound is selected from the group consisting of glucose and polyethylenimine derivatives.
- 25. (Twice Amended) The method of Claim 24, wherein the polyethyleninine polyethyleneimine derivative targets a the mannose receptor found on the surface of antigen presenting cells.
- 26. The method of Claim 25, wherein the derivative is mannosylated polyetheylenimine.
- 27. (Cancelled).
- 28. The method of Claim 23, wherein the complex is electrostatically neutral.
- 29. (Cancelled)
- 30. (Twice Amended) The method of Claim 298, wherein the complex comprises a 5:1 molar equivalent ratio of polyethylenimine derivative amine nitrogen per molar equivalent of DNA phosphate.
- 31. The method of Claim 23, wherein the gene delivery complex is formulated in a glucose solution.
- 32. The method of Claim 31, wherein the glucose solution is 5-10% glucose.

Serial No. 10/081,922 Express Mail Label No. ER 485041242 US Atty Docket No. RGT 9771

- 33. The method of Claim 32, wherein the glucose solution is 8% glucose.
- 34. (Cancelled)
- 35. (Twice Amended) The method of Claim 23, further comprising one or more steps selected from the group consisting of receptor stimulation, toxin activation, or tissue <u>injury</u> or <u>and</u> cell injury.
- 36. (Cancelled)
- 37. The method of Claim 23, wherein the lentivirus is protein is from a human immunodeficiency virus.
- 38. The method of Claim 37, wherein the human immunodeficiency virus is replication-defective.
- 39. The method of Claim 38, wherein the human immunodeficiency virus is integration-defective.
- 40. The method of Claim 23, wherein the DNA is a plasmid.
- 41. The method of Claim 23, wherein the cells are Langerhans cells.
- 42. (Amended) The method of Claim 29, wherein the complex comprises <u>a</u> 3:1 <u>ratio molar equivalent of polyethylenimine amine nitrogen</u> per molar equivalent of DNA phosphate.
- 43. (New) The method of Claim 25, wherein the derivative is a sugar-modified polyethylenimine.